EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures
September 12 2024 - 12:00PM
Business Wire
EGLE Therapeutics, a clinical-stage biotechnology company
uniquely positioned to advance the next generation of regulatory T
cell-focused therapies for oncology and auto-immunity, announced
today the appointment of Michel Detheux Ph.D, as Chairman of the
Board and Independent Board Member, and Mojgan Hossein-Nia as
Director representative of Takeda Ventures.
“We are thrilled to welcome Michel Detheux and Mojgan
Hossein-Nia to our Board of Directors. Michel and Mojgan’s
expertise and outstanding track record will be invaluable to Egle
as we advance our clinical pipeline of novel therapies addressing
the unmet medical need of patients with advanced cancer and
autoimmune diseases. Their expertise in the field of oncology and
their experience are instrumental for us to successfully execute on
our strategic priorities,” said Vincent Brichard, M.D., EGLE’s
Interim CEO and Board member.
“With the role of regulatory T cells becoming clearer in
oncology and auto-immunity, I am excited to join the Board of Egle
in order to help the team to move their differentiated pipeline
toward a clinical proof of concept and help patients with
innovative drugs targeting IL-2,” said Michel Detheux, independent
chairman at Egle and CEO of iTeos Therapeutics.
“I am excited to join the Board of Egle in order to help the
team strategize and continue to advance their pipeline to help
patients in areas of unmet needs,” said Mojgan Hossein-Nia, Board
Member at Egle Therapeutics.
Michel Detheux, Ph.D, Michel has held the role of Chief
Executive Officer at iTeos Therapeutics since the company’s
inception in 2012. During his tenure, Michel has led the company
from its origins to NASDAQ listing, raising $335MM in 2020 through
a crossover round and IPO. More recently, he spearheaded the
strategic collaboration with GlaxoSmithKline in 2021 to co-develop
and co-commercialize iTeos’ differentiated anti-TIGIT antibody for
a total value of $2B. He previously served as a director at Ludwig
Cancer Research and worked in various scientific and business
development roles at Ogeda (f/k/a Euroscreen).
Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in
Biochemistry from Université Catholique de Louvain, and a business
certificate from Solvay Business School.
Mojgan Hossein-Nia, Ph.D., Mojgan is the Head of R&D
Global Portfolio Strategy and Strategic Finance, Research and
Development at Takeda. She joined the company in September 2017 and
currently directs portfolio strategy and management across all
therapeutic areas facilitating investment decisions and overseeing
R&D governance process. Additionally, she manages enabling
capabilities that support portfolio management including the center
of operational performance and integrated portfolio/finance digital
solutions. In previous roles, she led the R&D investor
relations group and built up the R&D Partnership Office, which
was created to manage the overall health of R&D’s pipeline
partnerships and their integration into R&D processes.
Before joining Takeda, Mojgan worked at Novartis
Pharmaceuticals, building and leading multiple global functions
across R&D. Mojgan’s career spans over 30 years, comprising
dedicated roles in development outsourcing, global program
leadership and project management, business development &
licensing, and across multiple therapeutic areas including
cardiovascular, metabolism, and cell & gene therapies.
Dr. Hossein-Nia holds a B.Sc, and Ph.D. in biochemistry from
University of London, UK, and a diploma in pharmaceutical medicine
from University of Surrey, UK.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on
developing immunotherapies targeting suppressive regulatory T
cells. Egle is leveraging a proprietary discovery platform to
unveil novel Treg specific targets and to develop innovative
Treg-focused drug candidates for oncology and autoimmune diseases.
Egle aspires to advance toward the clinic its most advanced drug
candidates, EGL-001 (a potential best-in-class Treg-selective
anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager),
which are currently in IND-enabling studies.
Find out more at www.egle-tx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240912516511/en/
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57